Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.

Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.